43
Participants
Start Date
August 20, 2024
Primary Completion Date
July 31, 2030
Study Completion Date
September 2, 2030
Cilta-cel
Cilta-cel infusion will be administered intravenously.
Talquetamab
Talquetamab will be administered subcutaneously.
Daratumumab
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
Teclistamab
Teclistamab will be administered subcutaneously.
Bortezomib
Bortezomib will be administered subcutaneously as a part of induction.
Lenalidomide
Lenalidomide will be administered orally as a part of induction.
Dexamethasone
Dexamethasone will be administered orally as a part of induction.
Cyclophosphamide
Cyclophosphamide will be administered intravenously as a part of conditioning regimen.
Fludarabine
Fludarabine will be administered intravenously as a part of conditioning regimen.
Peter MacCallum Cancer Centre, Melbourne
The Alfred Hospital, Melbourne
Memorial Sloan Kettering Cancer Center, New York
Hosp. Univ. 12 de Octubre, Madrid
Levine Cancer Institute, Charlotte
Hosp Clinico Univ de Salamanca, Salamanca
Hosp. Univ. Marques de Valdecilla, Santander
University of Iowa Hospital and Clinics, Iowa City
Universitaetsklinikum Heidelberg, Heidelberg
Universitaetsklinikum Tuebingen, Tübingen
City of Hope, Duarte
University of California San Francisco, San Francisco
Universitatsklinikum Wurzburg, Würzburg
Instituto D Or de Pesquisa e Ensino, Salvador
Fundacao Antonio Prudente A C Camargo Cancer Center, São Paulo
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo
Janssen Research & Development, LLC
INDUSTRY